Taiho Pharmaceutical Co., Ltd and Nordic Group BV Enter Into a Development and Commercialization Agreement for the Recently EMA Approved Anti-Cancer Drug Teysuno[TM] Covering the EU and Other Selected European Countries
Paris (ots/PRNewswire) - Taiho Pharmaceutical Co., Ltd. and Nordic Group BV (Head office: Hoofddorp, the Netherlands ; CEO and Managing Director: Drs. Hans Schram) have entered into an agreement to support the ongoing development and commercialization of Teysuno[TM] in the EU and other selected European countries. ...
plus